Can Patients with HER2-Low Breast Cancer Benefit from Anti-HER2 Therapies? A Review
Jin Wang,Dongying Liao,Xuemin Zhang,Changhong Miao,Kuang Chen
DOI: https://doi.org/10.2147/BCTT.S407181
2023-04-22
Breast Cancer: Targets and Therapy
Abstract:Jin Wang, 1– 3, &ast Dongying Liao, 1– 3, &ast Xuemin Zhang, 1– 3 Changhong Miao, 1– 3 Kuang Chen 1– 3 1 Department of Emergency, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, People's Republic of China; 2 National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, People's Republic of China; 3 Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, People's Republic of China &astThese authors contributed equally to this work Correspondence: Kuang Chen, Department of Emergency, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Anshanxi Road, Nankai District, Tianjin, 300193, People's Republic of China, Tel +86 18622150281, Email Breast cancer (BC) poses a severe threat to the health of women worldwide. Currently, different therapeutic regimens are used for BC according to the pathological classification of HER2-positive or HER2-negative. Clinical reports of HER2-low expression indicate that the condition is HER2-negative, which was ineligible for HER2-targeted therapy. In contrast to HER2-zero tumors, however, HER2-low BC is a heterogeneous disease with unique genetic characteristics, prognoses, and different therapeutic responses. Clinical efficacy has been demonstrated by numerous potent and innovative anti-HER2 medications, particularly antibody–drug conjugates (ADCs). Certain ADCs, including T-DXd, have demonstrated good efficacy in some trials either used alone or in conjunction with other medications. To enhance outcomes in individuals with HER2-low BC, immunotherapy and other treatments are frequently combined with HER2-targeted therapy. There are also alternative strategies that target both HER2 and HER3 or other antigenic sites. We hope more individuals with HER2-low BC will benefit from more precise treatment regimens in the future. This article provides a review of existing research and clinical trials. Keywords: HER2-low breast cancer, monoclonal antibodies, antibody–drug conjugates, trastuzumab deruxtecan, immunotherapy Breast cancer (BC) has become the most commonly diagnosed tumor in women worldwide. 1 Human epidermal growth factor receptor 2 (HER2)-positive BC accounted for about 15% of all cases and was considered a poor prognostic predictor in the past. However, the survival outcomes of these patients have improved considerably and were similar to HER2-negative with the evolution of anti-HER2 agents. 2–6 In the past, HER2-low BC could not gain clinical benefit from conventional anti-HER2 agents like trastuzumab. 7 However, with the introduction of novel anti-HER2 compounds, BC with low levels of HER2 expression and no detectable Erb-B2 receptor tyrosine kinase 2 (ERBB2) gene amplification might also derive benefit. The efficacy was found when anti-HER2 agents were combined with other therapies such as immunotherapy. According to the updated 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines, the HER2 status is assessed to evaluate HER2 protein expression levels by IHC (immunohistochemistry) and HER2 gene status by ISH (in situ hybridization). 8 HER2-low is defined as IHC1+ or IHC2+ without gene amplification, accounting for about 55%. 9,10 The application of the new guidelines leads to an increase in the negativity rate on HER2 testing for the reclassification of Group 2 and Group 4 cases. 11 The refinement of future diagnostics may be needed to assess HER2 status more accurately. Based on the expression of hormone receptors (HR) and the status of HER2, BC is classified into four intrinsic molecular subtypes: luminal A (HR-positive and HER2-negative), luminal B (HR-positive and HER2-positive), HER2 enriched (HR-negative and HER2-positive), and triple-negative BC (TNBC, HR-negative and HER2-negative). 12 The four subtypes of tumors have different prognoses, and TNBC is generally considered to be the worst. 13 The possibility of improving the treatment of HER2-low BC has great clinical significance. Also, different treatment approaches for the four subtypes, respectively. In clinical practice, HER2-low BC was reported as HER2-negative, which was classified as TNBC or luminal-like. However, HER2-low BC is a heterogeneous disease, which showed distinctive molecular features. 9,14 Compared with HER2-zero tumors, HER2-low BC has a higher rate of HR-positive (64–88%), 9,15 a higher disease-free survival (DFS) and overall survival (OS), 16 and a limited immune response. 17 This implies that they may have differences in response to therapy, and different therapeutic strategies are nee -Abstract Truncated-